Lilly ' s Tirzepatide Achieved up to 15.7% Weight Loss in Adults with Obesity or Overweight and Type 2 Diabetes in SURMOUNT-2

INDIANAPOLIS, April 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that tirzepatide (10 mg and 15 mg) achieved superior weight loss compared to placebo at 72 weeks of treatment in results from SURMOUNT-2. The study met...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials